|
|
Welcome to the humangenetics startpage
Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, Jager N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rucker FG, Dohner K, Dohner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO, (2012). Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations.. Cell 148:59-71.
Abstract
Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA, (2012). Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.. J Mol Diagn 14:168-75.
Abstract
Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE, (2012). Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma.. Clin Cancer Res 18:808-14.
Abstract
Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ, (2011). Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.. Eur J Cancer :.
Abstract
de Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, Richel DJ, Vermeulen L, Medema JP, (2011). Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients.. Cell Stem Cell 9:476-85.
Abstract
Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Ora I, Speleman F, Caron HN, Versteeg R, (2012). Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis.. Genes Chromosomes Cancer 51:10-9.
Abstract
De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J, (2011). miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.. Clin Cancer Res 17:7684-92.
Abstract
Bunt J, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M, (2011). Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.. PLoS One 6:e26058.
Abstract
Teller K, Illner D, Thamm S, Casas-Delucchi CS, Versteeg R, Indemans M, Cremer T, Cremer M, (2011). A top-down analysis of Xa. Nucleus 2:465-77.
Abstract
Bunt J, Hasselt NE, Zwijnenburg DA, Hamdi M, Koster J, Versteeg R, Kool M, (2011). OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells.. Int J Cancer :.
Abstract
Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Ora I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ, (2011). Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.. Oncogene :.
Abstract
Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ, (2011). Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe.. Endocr Relat Cancer 18:657-68.
Abstract
Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B, Antonacci F, Sudmant P, Schulte JH, Roy NV, Vergult S, Buckley PG, Paepe AD, Noguera R, Versteeg R, Stallings R, Eggert A, Vandesompele J, Preter KD, Speleman F, (2011). Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.. Int J Cancer :.
Abstract
Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL, (2011). Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.. Mol Carcinog 50:403-11.
Abstract
Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA, (2011). The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.. Eur J Cancer 47:1193-202.
Abstract
Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL, (2010). Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.. Mol Carcinog :.
Abstract
Mokry M, Hatzis P, de Bruijn E, Koster J, Versteeg R, Schuijers J, van de Wetering M, Guryev V, Clevers H, Cuppen E, (2010). Efficient double fragmentation ChIP-seq provides nucleotide resolution protein-DNA binding profiles.. PLoS One 5:e15092.
Abstract
Bunt J, de Haas TG, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M, (2010). Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines.. Mol Cancer Res 8:1344-57.
Abstract
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F, (2010). Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.. Clin Cancer Res 16:4353-62.
Abstract
Buckley PG, Das S, Bryan K, Watters KM, Alcock L, Koster J, Versteeg R, Stallings RL, (2011). Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions.. Int J Cancer 128:2296-305.
Abstract
Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R, (2010). NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.. Cell 142:218-29.
Abstract
Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R, Caron HN, Molenaar JJ, Ora I, Eva A, Puppo M, Varesio L, (2010). A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.. Mol Cancer 9:185.
Abstract
Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, Koster J, Danen EH, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E, (2010). Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells.. Endocr Relat Cancer 17:399-414.
Abstract
Molenaar JJ, Ebus ME, Koster J, Santo E, Geerts D, Versteeg R, Caron HN, (2010). Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells.. Oncogene 29:2739-45.
Abstract
Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, Kool M, (2010). Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.. Cancer Res 70:762-71.
Abstract
Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS, (2010). The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.. Int J Cancer 126:2012-24.
Abstract
Revet I, Huizenga G, Koster J, Volckmann R, van Sluis P, Versteeg R, Geerts D, (2010). MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.. Cancer Lett 289:195-207.
Abstract
Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN, (2009). Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.. Proc Natl Acad Sci U S A 106:12968-73.
Abstract
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA, (2009). Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.. Clin Chem 55:1316-26.
Abstract
Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, Eggert A, Schramm A, (2009). Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness.. Oncogene 28:2015-23.
Abstract
Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R, (2009). ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.. Cancer Cell 15:328-40.
Abstract
Wu Y, Versteeg R, Slater L, LaBrecque D, (2009). Calcite precipitation dominates the electrical signatures of zero valent iron columns under simulated field conditions.. J Contam Hydrol 106:131-43.
Abstract
van Hooff SR, Koster J, Hulsen T, van Schaik BD, Roos M, van Batenburg MF, Versteeg R, van Kampen AH, (2009). The construction of genome-based transcriptional units.. OMICS 13:105-14.
Abstract
Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, Pritchard-Jones K, Kool M, Shipley J, (2009). Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.. Genes Chromosomes Cancer 48:455-67.
Abstract
Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schule R, Eggert A, Buettner R, Kirfel J, (2009). Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.. Cancer Res 69:2065-71.
Abstract
Schulte JH, Pentek F, Hartmann W, Schramm A, Friedrichs N, Ora I, Koster J, Versteeg R, Kirfel J, Buettner R, Eggert A, (2009). The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo.. Int J Cancer 124:2488-94.
Abstract
van Engelen K, Merks JH, Lam J, Kremer LC, Backes M, Baars MJ, van der Pal HJ, Postma AV, Versteeg R, Caron HN, Mulder BJ, (2009). Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literature.. Eur J Pediatr 168:1081-90.
Abstract
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA, (2008). PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.. J Clin Oncol 26:5443-9.
Abstract
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R, (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.. PLoS One 3:e3088.
Abstract
de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M, (2008). Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.. Clin Cancer Res 14:4154-60.
Abstract
Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN, (2008). Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.. Cancer Res 68:2599-609.
Abstract
Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, Versteeg R, Cuppen E, van de Wetering M, Clevers H, Stunnenberg HG, (2008). Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells.. Mol Cell Biol 28:2732-44.
Abstract
Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Ora I, Versteeg R, Geerts D, (2008). The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma.. Exp Cell Res 314:707-19.
Abstract
Koppen A, Ait-Aissa R, Koster J, Ora I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ, (2008). Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.. Int J Cancer 122:1455-64.
Abstract
Wu Y, Slater L, Versteeg R, LaBrecque D, (2008). A comparison of the low frequency electrical signatures of iron oxide versus calcite precipitation in granular zero valent iron columns.. J Contam Hydrol 95:154-67.
Abstract
Geerts D, Wallick CJ, Koomoa DL, Koster J, Versteeg R, Go RC, Bachmann AS, (2007). Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation.. Clin Cancer Res 13:6312-9.
Abstract
Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ, (2007). Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma.. Eur J Cancer 43:2413-22.
Abstract
Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A, Laureys G, Van Roy N, Speleman F, (2007). ArrayCGH-based classification of neuroblastoma into genomic subgroups.. Genes Chromosomes Cancer 46:1098-108.
Abstract
Gierman HJ, Indemans MH, Koster J, Goetze S, Seppen J, Geerts D, van Driel R, Versteeg R, (2007). Domain-wide regulation of gene expression in the human genome.. Genome Res 17:1286-95.
Abstract
Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ, (2007). Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.. Cancer Lett 256:218-28.
Abstract
Zinner R, Teller K, Versteeg R, Cremer T, Cremer M, (2007). Biochemistry meets nuclear architecture: multicolor immuno-FISH for co-localization analysis of chromosome segments and differentially expressed gene loci with various histone methylations.. Adv Enzyme Regul 47:223-41.
Abstract
Henriksen JR, Lokke C, Hammero M, Geerts D, Versteeg R, Flaegstad T, Einvik C, (2007). Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines.. Nucleic Acids Res 35:e67.
Abstract
Goetze S, Mateos-Langerak J, Gierman HJ, de Leeuw W, Giromus O, Indemans MH, Koster J, Ondrej V, Versteeg R, van Driel R, (2007). The three-dimensional structure of human interphase chromosomes is related to the transcriptome map.. Mol Cell Biol 27:4475-87.
Abstract
Kester MH, Kuiper GG, Versteeg R, Visser TJ, (2006). Regulation of type III iodothyronine deiodinase expression in human cell lines.. Endocrinology 147:5845-54.
Abstract
de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L, Perera M, Corte G, Wirths O, van Sluis P, Pietsch T, Troost D, Baas F, Versteeg R, Kool M, (2006). OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.. J Neuropathol Exp Neurol 65:176-86.
Abstract
Valentijn LJ, Koster J, Versteeg R, (2006). Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV.. Genomics 87:483-9.
Abstract
van Limpt V, Chan A, Schramm A, Eggert A, Versteeg R, (2005). Phox2B mutations and the Delta-Notch pathway in neuroblastoma.. Cancer Lett 228:59-63.
Abstract
Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt V, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A, (2005). Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.. Cancer Lett 228:143-53.
Abstract
Geerts D, Revet I, Jorritsma G, Schilderink N, Versteeg R, (2005). MEIS homeobox genes in neuroblastoma.. Cancer Lett 228:43-50.
Abstract
Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R, (2005). Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes.. Cancer Res 65:3136-45.
Abstract
Hienonen T, Sammalkorpi H, Isohanni P, Versteeg R, Karikoski R, Aaltonen LA, (2005). A 17p11.2 germline deletion in a patient with Smith-Magenis syndrome and neuroblastoma.. J Med Genet 42:e3.
Abstract
van Limpt V, Schramm A, van Lakeman A, Sluis P, Chan A, van Noesel M, Baas F, Caron H, Eggert A, Versteeg R, (2004). The Phox2B homeobox gene is mutated in sporadic neuroblastomas.. Oncogene 23:9280-8.
Abstract
van Noesel MM, Versteeg R, (2004). Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.. Gene 325:1-15.
Abstract
van Noesel MM, van Bezouw S, Voute PA, Herman JG, Pieters R, Versteeg R, (2003). Clustering of hypermethylated genes in neuroblastoma.. Genes Chromosomes Cancer 38:226-33.
Abstract
Versteeg R, van Schaik BD, van Batenburg MF, Roos M, Monajemi R, Caron H, Bussemaker HJ, van Kampen AH, (2003). The human transcriptome map reveals extremes in gene density, intron length, GC content, and repeat pattern for domains of highly and weakly expressed genes.. Genome Res 13:1998-2004.
Abstract
van Noesel MM, Pieters R, Voute PA, Versteeg R, (2003). The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis.. Cancer Lett 197:165-72.
Abstract
Geerts D, Schilderink N, Jorritsma G, Versteeg R, (2003). The role of the MEIS homeobox genes in neuroblastoma.. Cancer Lett 197:87-92.
Abstract
Van Limpt VA, Chan AJ, Van Sluis PG, Caron HN, Van Noesel CJ, Versteeg R, (2003). High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type.. Int J Cancer 105:61-9.
Abstract
Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN, (2003). Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma.. Genes Chromosomes Cancer 36:242-9.
Abstract
Van Roy N, Vandesompele J, Berx G, Staes K, Van Gele M, De Smet E, De Paepe A, Laureys G, van der Drift P, Versteeg R, Van Roy F, Speleman F, (2002). Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients.. Genes Chromosomes Cancer 35:113-20.
Abstract
Godfried MB, Veenstra M, Valent A, Sluis P, Voute PA, Versteeg R, Caron HN, (2002). Lack of interstitial chromosome 1p deletions in clinically-detected neuroblastoma.. Eur J Cancer 38:1513-9.
Abstract
Godfried MB, Veenstra M, v Sluis P, Boon K, v Asperen R, Hermus MC, v Schaik BD, Voute TP, Schwab M, Versteeg R, Caron HN, (2002). The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.. Oncogene 21:2097-101.
Abstract
van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB, Herman JG, Versteeg R, (2002). Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.. Cancer Res 62:2157-61.
Abstract
Spieker N, Beitsma M, Van Sluis P, Chan A, Caron H, Versteeg R, (2001). Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1.. Genes Chromosomes Cancer 31:172-81.
Abstract
Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R, (2001). N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis.. EMBO J 20:1383-93.
Abstract
Caron H, van Schaik B, van der Mee M, Baas F, Riggins G, van Sluis P, Hermus MC, van Asperen R, Boon K, Voute PA, Heisterkamp S, van Kampen A, Versteeg R, (2001). The human transcriptome map: clustering of highly expressed genes in chromosomal domains.. Science 291:1289-92.
Abstract
Spieker N, van Sluis P, Beitsma M, Boon K, van Schaik BD, van Kampen AH, Caron H, Versteeg R, (2001). The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32.. Genomics 71:214-21.
Abstract
Caron H, Spieker N, Godfried M, Veenstra M, van Sluis P, de Kraker J, Voute P, Versteeg R, (2001). Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted.. Genes Chromosomes Cancer 30:168-74.
Abstract
van Kampen AH, van Schaik BD, Pauws E, Michiels EM, Ruijter JM, Caron HN, Versteeg R, Heisterkamp SH, Leunissen JA, Baas F, van der Mee M, (2000). USAGE: a web-based approach towards the analysis of SAGE data. Serial Analysis of Gene Expression.. Bioinformatics 16:899-905.
Abstract
van Limpt V, Chan A, Caron H, Sluis PV, Boon K, Hermus MC, Versteeg R, (2000). SAGE analysis of neuroblastoma reveals a high expression of the human homologue of the Drosophila Delta gene.. Med Pediatr Oncol 35:554-8.
Abstract
Spieker N, Beitsma M, van Sluis P, Roobeek I, den Dunnen JT, Speleman F, Caron H, Versteeg R, (2000). An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis.. Genes Chromosomes Cancer 27:143-52.
Abstract
van der Drift P, Chan A, Zehetner G, Westerveld A, Versteeg R, (1999). Multiple MSP pseudogenes in a local repeat cluster on 1p36.2: An expanding genomic graveyard?. Genomics 62:74-81.
Abstract
Wuyts W, Spieker N, Van Roy N, De Boulle K, De Paepe A, Willems PJ, Van Hul W, Versteeg R, Speleman F, (1999). Refined physical mapping and genomic structure of the EXTL1 gene.. Cytogenet Cell Genet 86:267-70.
Abstract
Van Gele M, Van Roy N, Ronan SG, Messiaen L, Vandesompele J, Geerts ML, Naeyaert JM, Blennow E, Bar-Am I, Das Gupta TK, van der Drift P, Versteeg R, Leonard JH, Speleman F, (1998). Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas.. Genes Chromosomes Cancer 23:67-71.
Abstract
Van Gele M, Van Roy N, Jauch A, Laureys G, Benoit Y, Schelfhout V, De Potter CR, Brock P, Uyttebroeck A, Sciot R, Schuuring E, Versteeg R, Speleman F, (1997). Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis.. Eur J Cancer 33:1979-82.
Abstract
Van Roy N, Laureys G, Van Gele M, Opdenakker G, Miura R, van der Drift P, Chan A, Versteeg R, Speleman F, (1997). Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.. Eur J Cancer 33:1974-8.
Abstract
Van Roy N, Jauch A, Van Gele M, Laureys G, Versteeg R, De Paepe A, Cremer T, Speleman F, (1997). Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.. Cancer Genet Cytogenet 97:135-42.
Abstract
Versteeg R, (1997). Aberrant methylation in cancer.. Am J Hum Genet 60:751-4.
Abstract
Cheng NC, Beitsma M, Chan A, Op den Camp I, Westerveld A, Pronk J, Versteeg R, (1996). Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus.. Oncogene 13:1737-44.
Abstract
Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, de Kraker J, Voute PA, Vergnaud G, Westerveld A, Slater R, Versteeg R, (1996). Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus.. Hum Genet 97:834-7.
Abstract
Cheng NC, Chan AJ, Beitsma MM, Speleman F, Westerveld A, Versteeg R, (1996). A human modifier of methylation for class I HLA genes (MEMO-1) maps to chromosomal bands 1p35-36.1.. Hum Mol Genet 5:309-17.
Abstract
Hofstra RM, Cheng NC, Hansen C, Stulp RP, Stelwagen T, Clausen N, Tommerup N, Caron H, Westerveld A, Versteeg R, Buys CH, (1996). No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma.. Hum Genet 97:362-4.
Abstract
Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA, Versteeg R, (1996). Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.. N Engl J Med 334:225-30.
Abstract
van der Drift P, Chan A, Laureys G, van Roy N, Sickmann G, den Dunnen J, Westerveld A, Speleman F, Versteeg R, (1995). Balanced translocation in a neuroblastoma patient disrupts a cluster of small nuclear RNA U1 and tRNA genes in chromosomal band 1p36.. Genes Chromosomes Cancer 14:35-42.
Abstract
Van Roy N, Forus A, Myklebost O, Cheng NC, Versteeg R, Speleman F, (1995). Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP.. Cancer Genet Cytogenet 82:151-4.
Abstract
Laureys G, Speleman F, Versteeg R, van der Drift P, Chan A, Leroy J, Francke U, Opdenakker G, Van Roy N, (1995). Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers.. Oncogene 10:1087-93.
Abstract
Cheng NC, Van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, Versteeg R, (1995). Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.. Oncogene 10:291-7.
Abstract
Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voute PA, Delattre O, Laureys G, Van Roy N, et al., (1995). 1p36: every subband a suppressor?. Eur J Cancer 31A:538-41.
Abstract
Van Roy N, Cheng NC, Laureys G, Opdenakker G, Versteeg R, Speleman F, (1995). Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma.. Eur J Cancer 31A:530-5.
Abstract
Laureys G, Versteeg R, Speleman F, van der Drift P, Francke U, Opdenakker G, Van Roy N, (1995). Characterisation of the chromosome breakpoints in a patient with a constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12) and neuroblastoma.. Eur J Cancer 31A:523-6.
Abstract
van der Drift P, Chan A, van Roy N, Laureys G, Westerveld A, Speleman F, Versteeg R, (1994). A multimegabase cluster of snRNA and tRNA genes on chromosome 1p36 harbours an adenovirus/SV40 hybrid virus integration site.. Hum Mol Genet 3:2131-6.
Abstract
Caron H, van Sluis P, van Roy N, de Kraker J, Speleman F, Voute PA, Westerveld A, Slater R, Versteeg R, (1994). Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity.. Am J Hum Genet 55:341-7.
Abstract
Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, Speleman F, (1994). 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines.. Genes Chromosomes Cancer 10:103-14.
Abstract
Van Roy N, Laureys G, Versteeg R, Opdenakker G, Speleman F, (1993). High-resolution fluorescence mapping of 46 DNA markers to the short arm of human chromosome 1.. Genomics 18:71-8.
Abstract
Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voute PA, Westerveld A, Versteeg R, (1993). Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification.. Nat Genet 4:187-90.
Abstract
Boschman GA, Rens W, Manders EM, Slater RM, Versteeg R, Aten JA, (1992). Detection of recurrent chromosome abnormalities in Ewing's sarcoma and peripheral neuroectodermal tumor cells using bivariate flow karyotyping.. Genes Chromosomes Cancer 5:375-84.
Abstract
Versteeg R, (1992). NK cells and T cells: mirror images?. Immunol Today 13:244-7.
Abstract
Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van t Veer LJ, Kruse-Wolters KM, (1991). Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression?. Semin Cancer Biol 2:73-83.
Abstract
Versteeg R, van der Minne C, Plomp A, Sijts A, van Leeuwen A, Schrier P, (1990). N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells.. Mol Cell Biol 10:5416-23.
Abstract
Versteeg R, Peltenburg LT, Plomp AC, Schrier PI, (1989). High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells.. J Immunol 143:4331-7.
Abstract
Versteeg R, Kruse-Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, Ruiter DJ, Schrier PI, (1989). Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific.. J Exp Med 170:621-35.
Abstract
van t Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL, (1989). N-ras mutations in human cutaneous melanoma from sun-exposed body sites.. Mol Cell Biol 9:3114-6.
Abstract
Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI, (1988). c-myc down-regulates class I HLA expression in human melanomas.. EMBO J 7:1023-9.
Abstract
Konings A, Hupkes P, Versteeg R, Grosveld G, Reuser A, Galjaard H, (1984). Cloning a cDNA for the lysosomal alpha-glucosidase.. Biochem Biophys Res Commun 119:252-8.
Abstract
Van der Avoort HG, Teertstra R, Versteeg R, Weisbeek PJ, (1983). Genes and regulatory sequences of bacteriophage phi X174.. Biochim Biophys Acta 741:94-102.
Abstract
|
|
|
Microarray experiments are popular approaches to investigate a wide range of hypotheses in modern biological research.The analysis and visualization of these high throughput experiments is often a tedious undertaking, especially for the biologists who performed the experiments.In the department of human genetics, we have build a web-based platform called R2 to aid in the analysis and visualization of Affymetrix microarray datasets (tumor series, as well as experiments). An increasing number of analyses and visualizations can be performed in R2, which are accessible via a user-friendly interface. This makes the system intuitive and easy to use for biologists. R2 also supports the possibility to export data for use in various other applications, thereby increasing the usability of the program. Due to its modular structure, R2 is highly flexible and can easily be extended with new functionality. Currently R2 supports all major chip designs for human/mouse/rat and harbors over 19.000 Affymetrix microarray samples. |
|
|
|
|
|
